Camp for Children With Cancer Has Its 15th Anniversary

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 10
Volume 6
Issue 10

IDYLLWILD, Calif-Actor Dustin Hoffman joined “Ronald McDonald,” the McDonald’s restaurant clown, and nearly 100 campers and their families in celebrating the 15th anniversary of Camp Ronald McDonald for Good Times-one of the nation’s oldest and largest year-round recreational camping programs for children with cancer.

IDYLLWILD, Calif—Actor Dustin Hoffman joined “Ronald McDonald,” the McDonald’s restaurant clown, and nearly 100 campers and their families in celebrating the 15th anniversary of Camp Ronald McDonald for Good Times—one of the nation’s oldest and largest year-round recreational camping programs for children with cancer.

The camp is a program of Ronald McDonald House Charities and is cost-free to children with cancer and their families. Ronald McDonald House Charities gives grants to other programs throughout the country that provide camps for children with cancer.

As part of the anniversary celebration, children and families participated in outdoor activities and were given a demonstration of the new courage course, which includes a 50-foot climbing tower. At the end of the day, two-time Oscar winner Hoffman put his acting skills to the test reading ghost stories to the children around a camp fire.

The celebration also included dedication of a new medical complex consisting of an infirmary, sleeping ward, and the Hickman building for campers with catheter tubes needing specialized supervision before and after camp activities. With a rustic camping decor, the medical complex was purposely designed not to look or feel like a hospital.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content